Zimmer Biomet’s (ZBH) “Buy” Rating Reiterated at Argus

by · The Markets Daily

Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Argus in a research note issued to investors on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s target price suggests a potential upside of 27.64% from the company’s previous close.

Several other brokerages have also weighed in on ZBH. Royal Bank Of Canada increased their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Canaccord Genuity Group increased their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays upgraded shares of Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Finally, Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $104.47.

Read Our Latest Stock Analysis on ZBH

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded up $3.08 during trading hours on Thursday, reaching $97.94. 409,356 shares of the stock were exchanged, compared to its average volume of 2,222,952. The stock has a market cap of $18.68 billion, a P/E ratio of 23.84, a P/E/G ratio of 1.81 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $104.15. The firm’s 50 day moving average is $95.18 and its 200 day moving average is $91.41.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. Zimmer Biomet’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts predict that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $1,344,282,000. State Street Corp raised its stake in Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after acquiring an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $328,578,000. Dimensional Fund Advisors LP increased its stake in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after buying an additional 24,208 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $187,480,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

Read More